Trials, Sales Wins Sends Jazz Pharmaceuticals Higher

JAZZ develops and sells treatments for narcolepsy, oncology, pain, and psychiatry, including Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. In its third-quarter fiscal 2025 earnings report, JAZZ reported $1.126 billion in revenue (a 7% annual jump), two regulatory approvals, $2 billion in cash and investments on hand, and full-year revenue guidance of up to $4.275 billion.

It’s no wonder JAZZ shares are up 36% so far this year – and they could rise more. MoneyFlows data shows how Big Money investors are again betting heavily on the stock.

Big Money Likes Jazz Pharmaceuticals’ Tune

Institutional volumes reveal plenty. In the last year, JAZZ has enjoyed strong investor demand, which we believe to be institutional support.

Each green bar signals unusually large volumes in JAZZ shares. They reflect our proprietary inflow signal, pushing the stock higher:

Plenty of health care names are under accumulation right now. But there’s a powerful fundamental story happening with Jazz Pharmaceuticals.

Jazz Pharmaceuticals Fundamental Analysis

Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, JAZZ has had strong sales and earnings growth:

• 3-year sales growth rate (+9.7%)
• 3-year EPS growth rate (+36.7%)

Source: FactSet

Also, EPS is estimated to ramp higher this year by +184%.

Now it makes sense why the stock has been generating Big Money interest. JAZZ has a track record of strong financial performance.

Marrying great fundamentals with MoneyFlows software has found some big winning stocks over the long term.

Jazz Pharmaceuticals has been a top-rated stock at MoneyFlows. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

The blue bars below show when JAZZ was a top pick on the Outlier 20 report in the last year…Big Money is buying in flurries:

Tracking unusual volumes reveals the power of money flows.

This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward.

Jazz Pharmaceuticals Price Prediction

The JAZZ action isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no position in JAZZ at the time of publication.

If you are a Registered Investment Advisor (RIA) or are a serious investor, take your investing to the next level and follow our free weekly MoneyFlows insights.